Healthcare · Medical - Diagnostics & Research
Price
$215.75
Market Cap
$10.4B
Employees
18,700
Beta
1.45
Avg Volume
869,964
CEO
James C. Foster
Business Description
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Business History
Price Overview
Last updated: Jun 28, 2026 5:23am (just now)$215.75
+3.04 (+1.43%)
Day Range
$210.00 – $217.19
52-Week Range
$144.26 – $228.88
50-Day MA
$176.75
200-Day MA
$178.97
Volume
1,035,754.00
Analyst Price Targets
Low
$192.00
Consensus
$214.14
High
$220.00
(41 analysts)
Share Structure
Outstanding
48,167,730.00
Float
47,578,639.00
Free Float
98.8%
High free float
— 98.8% of shares trade freely, ~1.2% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-74.14
Stock Price: $215.75
EPS (Diluted): -2.91
EPS (Diluted): -2.91
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
3.19
Stock Price: $215.75
Total Equity: $3.16B
Shares: 49,564,000
Total Equity: $3.16B
Shares: 49,564,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
45.62
Market Cap: $10.39B
Total Debt: $2.61B
Cash: $213.77M
EBITDA: $410.84M
Total Debt: $2.61B
Cash: $213.77M
EBITDA: $410.84M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$12.9B
Market Cap: $10.39B
Total Debt: $2.61B
Cash: $213.77M
Total Debt: $2.61B
Cash: $213.77M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
2.51
Stock Price: $215.75
Revenue: $4.02B
Shares: 49,564,000
Revenue: $4.02B
Shares: 49,564,000
EV/Sales (Total value vs revenue — works when P/E can't)
API3.22
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
30.5%
Gross Profit: $1.23B
Revenue: $4.02B
Revenue: $4.02B
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
12.6%
Operating Income: $507.84M
Revenue: $4.02B
Revenue: $4.02B
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-3.6%
Net Income: -$144.34M
Revenue: $4.02B
Revenue: $4.02B
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-5.7%
Net Income: -$144.34M
Total Equity: $3.16B
Total Equity: $3.16B
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
7.1%
Operating Income: $507.84M
Tax Rate: -42.9%
Equity: $3.16B
Total Debt: $2.61B
Cash: $213.77M
Tax Rate: -42.9%
Equity: $3.16B
Total Debt: $2.61B
Cash: $213.77M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
1.29
Current Assets: $1.45B
Current Liabilities: $1.12B
Current Liabilities: $1.12B
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.82
Short-Term Debt: $61.06M
Long-Term Debt: $2.55B
Total Debt: $2.61B
Total Equity: $3.16B
Long-Term Debt: $2.55B
Total Debt: $2.61B
Total Equity: $3.16B
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$81.01
Revenue: $4.02B
Shares: 49,564,000
Shares: 49,564,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$63.85
Total Equity: $3.16B
Shares: 49,564,000
Shares: 49,564,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$10.46
Operating CF: $737.65M
CapEx: -$219.15M
Shares: 49,564,000
CapEx: -$219.15M
Shares: 49,564,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $215.75
Stock Price: $215.75
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$144.34M
Net Income: -$144.34M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares CRL against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 28, 2026 5:23am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $3.5B | $4.0B | $4.1B | $4.0B | $4.0B |
| Cost of Revenue | $2.2B | $2.5B | $2.6B | $2.7B | $2.8B |
| Gross Profit | $1.3B | $1.5B | $1.5B | $1.3B | $1.2B |
| Operating Expenses | $744.8M | $811.7M | $885.3M | $1.1B | $717.7M |
| Operating Income | $589.9M | $651.0M | $617.3M | $227.3M | $507.8M |
| Net Income | $391.0M | $486.2M | $474.6M | $10.3M | -$144.3M |
| EBITDA | $820.2M | $986.1M | $1.0B | $581.1M | $410.8M |
| EPS | $7.77 | $9.57 | $9.27 | $0.20 | $-2.91 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 28, 2026 5:23am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $245.2M | $233.9M | $276.8M | $194.6M | $213.8M |
| Total Current Assets | $1.3B | $1.4B | $1.6B | $1.4B | $1.4B |
| Total Assets | $7.0B | $7.6B | $8.2B | $7.5B | $7.1B |
| Current Liabilities | $1.0B | $1.1B | $1.1B | $994.1M | $1.1B |
| Long-Term Debt | $2.9B | $2.7B | $2.6B | $2.2B | $2.5B |
| Total Liabilities | $4.4B | $4.6B | $4.5B | $4.0B | $3.9B |
| Total Equity | $2.5B | $3.0B | $3.6B | $3.5B | $3.2B |
| Retained Earnings | $980.8M | $1.4B | $1.9B | $1.8B | $1.4B |
Cash Flow (Annual)
Last updated: Jun 28, 2026 5:23am (just now)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $760.8M | $619.6M | $683.9M | $734.6M | $737.6M |
| Capital Expenditure | -$228.8M | -$324.7M | -$318.5M | -$233.0M | -$219.2M |
| Free Cash Flow | $532.0M | $294.9M | $365.4M | $501.6M | $518.5M |
| Acquisitions (net) | -$1.2B | -$120.1M | -$194.8M | -$5.5M | $17.4M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$40.7M | -$38.7M | -$24.2M | -$119.2M | -$360.7M |
| Net Change in Cash | $13.2M | -$5.1M | $43.3M | -$78.9M | $10.4M |
Analyst Estimates (Annual)
Last updated: Jun 28, 2026 5:23am (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$3.9B $3.9B – $4.0B
|
$4.1B $4.1B – $4.1B
|
$4.3B $4.2B – $4.3B
|
$4.3B $4.2B – $4.3B
|
| EBITDA |
$764.3M $754.5M – $784.0M
|
$798.2M $796.8M – $799.6M
|
$829.4M $820.2M – $845.4M
|
$829.5M $820.3M – $845.5M
|
| Net Income |
$607.4M $590.2M – $624.6M
|
$447.0M $434.6M – $816.7M
|
$724.0M $713.5M – $742.1M
|
$758.3M $747.4M – $777.3M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 28, 2026 5:23am (just now)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +12.3% | +3.9% | -1.9% | -0.9% |
| Gross Profit Growth | +9.6% | +2.7% | -11.4% | -8.0% |
| Operating Income Growth | +10.4% | -5.2% | -63.2% | +123.4% |
| Net Income Growth | +24.4% | -2.4% | -97.8% | -1,501.7% |
| EBITDA Growth | +20.2% | +4.7% | -43.7% | -29.3% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-05 | FOSTER JAMES C | G-Gift | 153,361.00 | $0.00 | $0 |
| 2026-06-05 | FOSTER JAMES C | G-Gift | 153,361.00 | $0.00 | $0 |
| 2026-06-05 | FOSTER JAMES C | G-Gift | 20,000.00 | $0.00 | $0 |
| 2026-06-05 | FOSTER JAMES C | G-Gift | 20,000.00 | $0.00 | $0 |
| 2026-06-05 | FOSTER JAMES C | G-Gift | 10,000.00 | $0.00 | $0 |
| 2026-06-05 | FOSTER JAMES C | G-Gift | 10,000.00 | $0.00 | $0 |
| 2026-06-05 | Girshick Birgit | G-Gift | 3,386.00 | $0.00 | $0 |
| 2026-06-05 | Girshick Birgit | G-Gift | 3,386.00 | $0.00 | $0 |
| 2026-06-05 | Parisotto Shannon M | G-Gift | 1,529.00 | $0.00 | $0 |
| 2026-06-05 | Parisotto Shannon M | G-Gift | 1,529.00 | $0.00 | $0 |
| 2026-06-02 | Barg Steven | A-Award | 422.00 | $174.79 | $73,761 |
| 2026-05-29 | Coleman Glenn | A-Award | 6,640.00 | $180.71 | $1.2M |
| 2026-05-29 | Mintz Mark | A-Award | 2,534.00 | $180.71 | $457,919 |
| 2026-05-30 | Mintz Mark | F-InKind | 305.00 | $180.71 | $55,117 |
| 2026-05-31 | Mintz Mark | F-InKind | 64.00 | $180.71 | $11,565 |
| 2026-05-29 | LaPlume Joseph W | A-Award | 5,257.00 | $180.71 | $949,992 |
| 2026-05-30 | LaPlume Joseph W | F-InKind | 744.00 | $180.71 | $134,448 |
| 2026-05-31 | LaPlume Joseph W | F-InKind | 235.00 | $180.71 | $42,467 |
| 2026-05-29 | Knell Michael Gunnar | A-Award | 1,837.00 | $180.71 | $331,964 |
| 2026-05-30 | Knell Michael Gunnar | F-InKind | 152.00 | $180.71 | $27,468 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for CRL — it's generated by the pipeline (
market-narrative step).
No community reviews yet for CRL.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30